Yoshiki Shiraishi

Dr. Yoshiki Shiraishi

Tokai University School of Medicine, Isehara, Kanagawa, Japan
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
FSFumitake Saito
Fumitake Saito
STSadatomo Tasaka
Sadatomo Tasaka
KIKen-Ichiro Inoue
Ken-Ichiro Inoue
KMKeisuke Miyamoto
Keisuke Miyamoto
YNYasushi Nakano
Yasushi Nakano
AIAkitoshi Ishizaka
Akitoshi Ishizaka
Interleukin-6 (IL-6) is known to be involved in the pathogenesis of various inflammatory diseases, but its role in bleomycin (BLM)-induced lung injury and subsequent fibrotic changes remains to be determined. We evaluated the role of IL-6 in the lung inflammatory changes induced by BLM using wild-type (WT) and IL-6–deficient (IL-6−/−) mice. The mice were treated intratracheally with 1 mg/kg BLM and killed 2, 7, or 21 days later. Lung Inflammation in the acute phase (Days 2 and 7) was assessed by differential cell counts in bronchoalveolar lavage (BAL) fluid and cytokine levels in the lung. Lung fibrotic changes were evaluated on Day 21 by histopathology and collagen assay. On Day 2, BLM administration induced significant increases in the numbers of total cells, macrophages, and neutrophils in BAL fluid, which were attenuated in IL-6−/− mice (P < 0.05). Lung pathology also showed inflammatory cell accumulation, which was attenuated in the IL-6−/− mice compared with WT mice. In WT mice, elevated levels of TGF-β1 and CCL3 were observed 2 and 7 days after BLM challenge, respectively. On Day 7, BLM-induced inflammatory cell accumulation did not differ between the genotypes. Lung pathology 21 days after BLM challenge revealed significant fibrotic changes with increased collagen content, which was attenuated in IL-6−/− mice. Although the TGF-β1 level in the lung did not differ between the genotypes on Day 21, CCL3 was significantly lower in IL-6−/− mice. These results indicate that IL-6 may play an important role in the pathogenesis of BLM-induced lung injury and subsequent fibrotic changes.

15 August 2008 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HZHaiying Zhang
Haiying Zhang
STSadatomo Tasaka
Sadatomo Tasaka
YSYoshiki Shiraishi
Yoshiki Shiraishi
KFKoichi Fukunaga
Koichi Fukunaga
WYWakako Yamada
Wakako Yamada
AIAkitoshi Ishizaka
Akitoshi Ishizaka
Rationale: The interaction of receptor for advanced glycation end products (RAGE) and its ligands often leads to inflammatory processes or tissue injury, although the effect of the blockade of RAGE signaling on lung injury remains to be investigated. Objectives: Using a murine model of lung injury induced by intratracheal lipopolysaccharide (LPS), we evaluated RAGE expression in the airspace and the effect of recombinant soluble RAGE (sRAGE) on LPS-induced lung injury. Methods: First, the expression of sRAGE in bronchoalveolar lavage (BAL) fluid was determined at 24 hours after intratracheal instillation of LPS or phosphate-buffered saline. Next, to evaluate the effect of sRAGE, BAL fluid was collected for cell counting and measurements of lung permeability and cytokine concentrations 24 hours after intratracheal LPS in the mice with or without intraperitoneal administration of sRAGE 1 hour after the instillation. In another series, lungs were sampled for histopathology and detection of apoptotic cells. The activation of nuclear factor (NF)-κB was analyzed 4 hours after LPS instillation. Measurements and Main Results: In response to LPS challenge, a RAGE isoform of 48 kD was detected in the BAL fluid. Treatment with sRAGE significantly attenuated the increases in neutrophil infiltration, lung permeability, production of inflammatory cytokines, NF-κB activation, and apoptotic cells in the lung as well as development of pathologic changes after LPS instillation. Conclusions: RAGE plays an important role in the pathogenesis of LPS-induced lung injury in mice. It was suggested that sRAGE should be tested as a treatment modality in other models of acute lung injury.

1 March 2005 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
YSYoshiki Shiraishi
Yoshiki Shiraishi
KAKoichiro Asano
Koichiro Asano
TNTakeshi Nakajima
Takeshi Nakajima
TOTsuyoshi Oguma
Tsuyoshi Oguma
YSYusuke Suzuki
Yusuke Suzuki
AIAkitoshi Ishizaka
Akitoshi Ishizaka
Mast cell-derived prostaglandin D2 (PGD2) is one of the essential modulators of eosinophilic airway inflammation in asthma and allergic rhinitis. Two G protein-coupled receptors for PGD2, prostaglandin D2 receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), are both expressed on the surface of eosinophils, and CRTH2 has been demonstrated to mediate PGD2-induced eosinophil mobilization in vitro. However, it has not yet been determined whether PGD2 and its receptors mediate in vivo eosinophil trafficking into the airways or other organs. We demonstrated that intratracheal administration of PGD2 in rats pretreated with systemic interleukin-5 (IL-5) injection induced marked airway eosinophilia, determined by the differential counts of cells in bronchoalveolar lavage (BAL) fluid and lung histology, within 2 h. Systemic IL-5 alone significantly increased the number of eosinophils in the peripheral blood but showed no effect on airway eosinophilia. Three CRTH2-specific agonists (13,14-dihydro-15-keto-PGD2, 11-deoxy-11-methylene-15-keto-PGD2, and indomethacin) demonstrated equivalent induction of BAL eosinophilia to that of PGD2, but a DP agonist (BW 245C [5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)-hydantoin]) or a thromboxane A2 receptor (TP) agonist ([1S-1α,2β(5Z), 3α(1E,3R*),4α)]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid) showed no effect. PGD2 or CRTH2 agonist-induced BAL eosinophilia was almost completely inhibited by pretreatment with a CRTH2/TP antagonist, ramatroban [BAY-u3405; (+)-(3R)-3-(4-fluorobenzenesulfonamido)-1,2,3,4-tetra-hydrocarbazole-9-propionic acid], whereas a TP-specific antagonist, SQ29,548 (5-heptenoic, 7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]-hept-2-yl]-[1S-[1α,2α(Z),3α,4α]]), or a DP-specific antagonist, BW A868C [3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexy-2-hydroxyethylamino)-hydantoin], did not inhibit the effects of PGD2. These results suggest that CRTH2 plays a significant role in the eosinophil trafficking from the bloodstream into the airways in PGD2-related airway inflammation.

18 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMSatomi Mitsuhashi
Satomi Mitsuhashi
KKKirill Kryukov
Kirill Kryukov
SNSo Nakagawa
So Nakagawa
JTJunko S. Takeuchi
Junko S. Takeuchi
YSYoshiki Shiraishi
Yoshiki Shiraishi
TITadashi Imanishi
Tadashi Imanishi
We developed a portable system for 16S rDNA analyses consisting of a nanopore technology-based sequencer, the MinION, and laptop computers, and assessed its potential ability to determine bacterial compositions rapidly. We tested our protocols using a mock bacterial community that contained equimolar 16S rDNA and a pleural effusion from a patient with empyema, for time effectiveness and accuracy. MinION sequencing targeting 16S rDNA detected all 20 of the bacterial species present in the mock bacterial community. Time course analysis indicated that the sequence data obtained during the first 5 minutes of sequencing (1,379 bacterial reads) were enough to detect all 20 bacteria in the mock sample and to determine species composition, consistent with results of those obtained from 4 hours of sequencing (24,202 reads). Additionally, using a clinical sample extracted from the empyema patient’s pleural effusion, we could identify major bacterial pathogens in that effusion using our rapid sequencing and analysis protocol. All results are comparable to conventional 16S rDNA sequencing results using an IonPGM sequencer. Our results suggest that rapid sequencing and bacterial composition determination are possible within 2 hours after obtaining a DNA sample.

1 May 2008 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
STSaeko Takahashi
Saeko Takahashi
HNHidetoshi Nakamura
Hidetoshi Nakamura
MSMakoto Seki
Makoto Seki
YSYoshiki Shiraishi
Yoshiki Shiraishi
MYMiyuki Yamamoto
Miyuki Yamamoto
AIAkitoshi Ishizaka
Akitoshi Ishizaka
Besides lowering cholesterol, statins exert multiple effects, such as anti-inflammatory activity and improvement of endothelial cell function. We examined whether simvastatin (SS) protects against the development of elastase-induced pulmonary emphysema in mice by using mean linear intercepts of alveoli (Lm) as a morphometric parameter of emphysema. After injection of intratracheal elastase on day 0, C57BL/6 mice were treated daily with SS (SS+ group) or PBS (SS− group) for 2 wk. A 21% decrease in Lm on day 7 was observed in the SS+ group vs. the SS− group. Anti-inflammatory effects of SS were observed as a decrease in percentage of neutrophils up to day 3, and in hydroxyproline concentration on day 3, in bronchoalveolar lavage fluid (BALF). SS also increased the number of proliferating cell nuclear antigen (PCNA)-positive alveolar epithelial cells between days 3 and 14. To confirm the role of statins in promoting proliferation of alveolar cells, mice were treated with SS (SS+) vs. PBS (SS−) for 12 days, starting 3 wk after elastase administration. After SS treatment, Lm decreased by 52% and PCNA-positive alveolar epithelial cells increased compared with the SS− group. Concentrations of vascular endothelial growth factor in BALF and endothelial nitric oxide synthase protein expression in pulmonary vessels tended to be higher in the SS+ group vs. the SS− group in this protocol. In conclusion, SS inhibited the development of elastase-induced pulmonary emphysema in mice. This therapeutic effect was due not only to anti-inflammation but also to the promotion of alveolar epithelial cell regeneration, partly mediated by restoring endothelial cell functions.

1 August 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MWMeiqin Wang
Meiqin Wang
KTKatsuyuki Takeda
Katsuyuki Takeda
YSYoshiki Shiraishi
Yoshiki Shiraishi
MOMasakazu Okamoto
Masakazu Okamoto
ADAzzeddine Dakhama
Azzeddine Dakhama
EGErwin W Gelfand
Erwin W Gelfand